Everomus 0.25mg Tablet

About

Everomus 0.25mg Tablet contains Everolimus, an immunosuppressant and antineoplastic agent belonging to the class of mTOR (mammalian target of rapamycin) inhibitors. It works by inhibiting the mTOR pathway, which plays a crucial role in cell growth, proliferation, and angiogenesis. In transplant settings, this inhibition helps prevent organ rejection by suppressing the immune system's response to the transplanted organ. In oncology, Everolimus targets specific pathways involved in cancer cell growth and survival, making it effective against certain types of tumors.

This medication is utilized in various clinical scenarios, including the prophylaxis of organ rejection in kidney and heart transplant recipients, and in the treatment of advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin, and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Its precise mechanism allows for targeted therapy, offering a valuable option for patients requiring immune modulation or cancer treatment.

Uses

• Prevention of organ rejection in kidney transplant recipients.
• Treatment of advanced renal cell carcinoma.
• Management of progressive neuroendocrine tumors.
• Therapy for subependymal giant cell astrocytoma.

Directions For Use

Take Everomus 0.25mg Tablet orally, once daily, at the same time each day, with or without food. Do not crush or chew the tablet; swallow it whole.

Benefits

• Effectively prevents organ transplant rejection.
• Slows the progression of certain cancers.
• Reduces tumor size in specific conditions.
• Offers a targeted therapy approach.
• Improves outcomes in transplant patients.
• Manages symptoms associated with certain tumors.

Side Effects

• Oral ulcers/stomatitis
• Rash
• Fatigue
• Diarrhea
• Nausea
• Peripheral edema
• Anemia
• Hyperglycemia
• Hyperlipidemia
• Infections (e.g., pneumonia)
• Proteinuria
• Interstitial lung disease

Safety Measures

• Alcohol - Avoid alcohol consumption as it may increase the risk of certain side effects or interact with the medication.
• Pregnancy - Everomus is generally contraindicated in pregnancy due to potential fetal harm. Use effective contraception during treatment and for 8 weeks after the last dose.
• Breastfeeding - It is not recommended during breastfeeding as Everolimus may pass into breast milk and harm the infant. Consult your doctor.
• Liver - Use with caution in patients with liver impairment; dose adjustments may be necessary. Close monitoring of drug levels and liver function is advised.
• Kidney - Use with caution in patients with kidney impairment. While not primarily renally cleared, monitoring of kidney function is important, especially in transplant patients.
• Lung - Everolimus can cause interstitial lung disease; monitor for new or worsening respiratory symptoms. Discontinuation may be required in severe cases.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.